This wiki has undergone a migration to Confluence found Here

Difference between revisions of "NHSN HAI R3D1.1 Comments"

From HL7Wiki
Jump to navigation Jump to search
(Created page with "==Instructions== '''31st Jan 2014 - NHSN R2D1.1 Available for Comments''' A minor update has been made to the NHSN Healthcare Associated Infection Reports, Release 2, US Rea...")
 
Line 3: Line 3:
 
'''31st Jan 2014 - NHSN R2D1.1 Available for Comments'''
 
'''31st Jan 2014 - NHSN R2D1.1 Available for Comments'''
  
A minor update has been made to the NHSN Healthcare Associated Infection Reports, Release 2, US Realm, September 2013, 1st DSTU Ballot (NHSN HAI R2D1). This update is available to HL7 members here [http://www.hl7.org/documentcenter/public/wg/structure/CDAR2_IG_HAIRPT_R2_D1_1_2014JAN.zip CDAR2_IG_HAIRPT_R2_D1_1_2014JAN.zip] as a point release named NHSN HAI R2D1.1 for commenting prior to reconciliation and publication. As a minor DSTU update, this new version will not go through the usual HL7 balloting process but will use the [http://gforge.hl7.org/gf/download/docmanfileversion/7482/10824/Guidance-to-Work-Groups-on-DSTU-Updates20130819.docx DSTU Update process] with industry review on the HL7 wiki. Because no changes were made to templates in this update, comments involving template modification are not in scope. The full list of changes in this release is documented in the update and can be summarized as:
+
'''24th August 2016 - NHSN HAI R3D1.1 Available for Comment'''
# Formatting the guide into two volumes
+
 
# Value set changes to NHSNCriterionOfDiagnosisCode
+
An update has been made to the NHSN HAI CDA Implementation Guide. 
During the two week comment period running from 1/31/2014 - 2/13/2014, please submit your comments on this wiki page including at least your name, item, existing wording, proposed wording, and comment. Thank you.
+
 
 +
This update is ''NHSN Healthcare Associated Infection (HAI) Reports Release 3, DSTU 1.1—US Realm, 1st Update to 1st HL7 Draft Standard for Trial Use (DSTU) (NHSN HAI R3D1.1)''. This update is available to HL7 members here: http://www.hl7.org/documentcenter/public/wg/structure/CDAR2_IG_HAIRPT_R3_D1.1_2016AUG_UPDATE_FOR_COMMENT.zip as a point release for commenting prior to reconciliation and publication.  
 +
 
 +
As a DSTU update, this new version will not go through the usual HL7 balloting process but will use the [http://gforge.hl7.org/gf/download/docmanfileversion/7482/10824/Guidance-to-Work-Groups-on-DSTU-Updates20130819.docx DSTU Update process] with industry review on the HL7 wiki.  
 +
 
 +
The full list of changes in this release is documented in the update and can be summarized as:
 +
 
 +
Three reports were revised:
 +
#     HAI Evidence of Infection (Dialysis) Report (V5)
 +
#    Hemovigilance (HV) Summary Report (V2)
 +
#    HAI AUR Antimicrobial Resistance Option (ARO) Report (V4)
 +
Two new templates were added:
 +
#    Blood Sample Collected for Culture Observation
 +
#    Pathogen Reduced Apheresis Platelet Usage Summary Observation
 +
Fourteen templates were revised:
 +
#    Antimicrobial Susceptibility Result Observation (V3)
 +
#    Antimicrobial Susceptibility Result Organizer (V3)
 +
#    Antimicrobial Susceptibility Tests Organizer (V3)
 +
#    Blood Product Usage Summary Observation (V2)
 +
#    Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2)
 +
#    Infection Indicator Organizer (V4)
 +
#    ISBT Product Code Summary Observation (V2)
 +
#    Isolate Susceptibility Tests Organizer (V3)
 +
#    IV Antibiotic Start Clinical Statement (V3)
 +
#    Specimen Collection Procedure (ARO) (V3)
 +
#    Summary Encounter (HV) (V2)
 +
#    Details Section in an Evidence of Infection (Dialysis) Report (V5)
 +
#    Findings Section in an ARO Report (V3)
 +
#    Summary Data Section (HV) (V2)
 +
Twelve new value sets were added:
 +
#    NHSN Red Blood Cells/Whole Blood Derived/S-303-Treated
 +
#    NHSN Red Blood Cells/Whole Blood Derived/Riboflavin-Treated
 +
#    NHSN Red Blood Cells/Apheresis/S-303-Treated
 +
#    NHSN Red Blood Cells/Apheresis/Riboflavin-Treated
 +
#    NHSN Cryoprecipitate/Psoralen-Treated
 +
#    NHSN Cryoprecipitate/Riboflavin-Treated
 +
#    NHSN Platelets/Apheresis/Psoralen-Treated and In Plasma
 +
#    NHSN Platelets/Apheresis/Psoralen-Treated and In Platelet Additive Solution
 +
#    NHSN Platelets/Apheresis/Riboflavin-Treated and In Plasma
 +
#    NHSN Platelets/Apheresis/Riboflavin-Treated and In Platelet Additive Solution
 +
#    NHSNPathogenReducedApheresisPlateletUsage
 +
#    NHSNDrugSusceptibilityTestMethod
 +
Six value sets were revised:
 +
#    NHSNHealthcareServiceLocationCode
 +
#    NHSNPathogenCode
 +
#    NHSNSpecimenTypeCode
 +
#    NHSNDrugSusceptibilityTestsCode
 +
#    NHSNCdiffTestMethod
 +
#     NHSNCriterionOfDiagnosisCode
 +
 
 +
During the two week comment period running from Wednesday 24 August 2016 - Wednesday 7 September 2016, please submit your comments on this page, including at least your name, item, existing wording, proposed wording, and comment. Thank you.

Revision as of 07:43, 24 August 2016

Instructions

31st Jan 2014 - NHSN R2D1.1 Available for Comments

24th August 2016 - NHSN HAI R3D1.1 Available for Comment

An update has been made to the NHSN HAI CDA Implementation Guide.

This update is NHSN Healthcare Associated Infection (HAI) Reports Release 3, DSTU 1.1—US Realm, 1st Update to 1st HL7 Draft Standard for Trial Use (DSTU) (NHSN HAI R3D1.1). This update is available to HL7 members here: http://www.hl7.org/documentcenter/public/wg/structure/CDAR2_IG_HAIRPT_R3_D1.1_2016AUG_UPDATE_FOR_COMMENT.zip as a point release for commenting prior to reconciliation and publication.

As a DSTU update, this new version will not go through the usual HL7 balloting process but will use the DSTU Update process with industry review on the HL7 wiki.

The full list of changes in this release is documented in the update and can be summarized as:

Three reports were revised:

  1. HAI Evidence of Infection (Dialysis) Report (V5)
  2. Hemovigilance (HV) Summary Report (V2)
  3. HAI AUR Antimicrobial Resistance Option (ARO) Report (V4)

Two new templates were added:

  1. Blood Sample Collected for Culture Observation
  2. Pathogen Reduced Apheresis Platelet Usage Summary Observation

Fourteen templates were revised:

  1. Antimicrobial Susceptibility Result Observation (V3)
  2. Antimicrobial Susceptibility Result Organizer (V3)
  3. Antimicrobial Susceptibility Tests Organizer (V3)
  4. Blood Product Usage Summary Observation (V2)
  5. Facility Transfuses Blood Products Treated with Pathogen Reduction Technology Observation (V2)
  6. Infection Indicator Organizer (V4)
  7. ISBT Product Code Summary Observation (V2)
  8. Isolate Susceptibility Tests Organizer (V3)
  9. IV Antibiotic Start Clinical Statement (V3)
  10. Specimen Collection Procedure (ARO) (V3)
  11. Summary Encounter (HV) (V2)
  12. Details Section in an Evidence of Infection (Dialysis) Report (V5)
  13. Findings Section in an ARO Report (V3)
  14. Summary Data Section (HV) (V2)

Twelve new value sets were added:

  1. NHSN Red Blood Cells/Whole Blood Derived/S-303-Treated
  2. NHSN Red Blood Cells/Whole Blood Derived/Riboflavin-Treated
  3. NHSN Red Blood Cells/Apheresis/S-303-Treated
  4. NHSN Red Blood Cells/Apheresis/Riboflavin-Treated
  5. NHSN Cryoprecipitate/Psoralen-Treated
  6. NHSN Cryoprecipitate/Riboflavin-Treated
  7. NHSN Platelets/Apheresis/Psoralen-Treated and In Plasma
  8. NHSN Platelets/Apheresis/Psoralen-Treated and In Platelet Additive Solution
  9. NHSN Platelets/Apheresis/Riboflavin-Treated and In Plasma
  10. NHSN Platelets/Apheresis/Riboflavin-Treated and In Platelet Additive Solution
  11. NHSNPathogenReducedApheresisPlateletUsage
  12. NHSNDrugSusceptibilityTestMethod

Six value sets were revised:

  1. NHSNHealthcareServiceLocationCode
  2. NHSNPathogenCode
  3. NHSNSpecimenTypeCode
  4. NHSNDrugSusceptibilityTestsCode
  5. NHSNCdiffTestMethod
  6. NHSNCriterionOfDiagnosisCode

During the two week comment period running from Wednesday 24 August 2016 - Wednesday 7 September 2016, please submit your comments on this page, including at least your name, item, existing wording, proposed wording, and comment. Thank you.